Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Inhibitors of Viral Protein Synthesis

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

Modified-Release Drug Delivery Systems: Rate-Programmed II

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...

Modified-Release Drug Delivery Systems: Rate-Programmed I

Modified-Release Drug Delivery Systems: Rate-Programmed I

Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...

Modified-Release Drug Delivery Systems: Drug Release Characteristics

Modified-Release Drug Delivery Systems: Drug Release Characteristics

Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

Modified-Release Drug Delivery Systems: Overview

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Contributions to Constructing Forced-Choice Questionnaires Using the Thurstonian IRT Model.

Multivariate behavioral research·2023

Same author

Outcomes and Predictors of Response to Pregabalin for the Treatment of Post-Traumatic Trigeminal Neuropathic Pain Following Neuroablative Procedures: A Retrospective Observational Study.

Pain physician·2023

Same author

Hydrazine-Assisted Acidic Water Splitting Driven by Iridium Single Atoms.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2023

Same author

A photoelectrochemical aptasensor for tetracycline based on the self-assembly of 2D MoS<sub>2</sub> on a 3D ZnO/Au/ITO electrode.

The Analyst·2023

Same author

Low-Background Signal-On Homogeneous Electrochemiluminescence Biosensor for Hepatitis B Virus Detection Based on the Regulation of the Length of DNA Modified on the Nanoparticles by CRISPR/Cas12a and Hybridization Chain Reaction.

Analytical chemistry·2023

Same author

Neonatal outcomes and related risk factors of 30 cases with aplastic anemia in pregnancy: A retrospective study.

Early human development·2023

Search research articles

Related Experiment Video

Updated: Jun 3, 2026

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Development of interferon alpha-2b microspheres with constant release.

Zhiping Li¹, Lin Li, Yan Liu

¹Beijing Institute of Pharmacology and Toxicology, 27 Taiping Road, Haidian District, Beijing 100850, China.

International Journal of Pharmaceutics

|March 23, 2011

Summary

This study developed novel microspheres for sustained delivery of Interferon alpha-2b (IFNα-2b), improving drug stability and release. The new method ensures constant and complete IFNα-2b release, enhancing patient compliance.

More Related Videos

Preparation of Cross-Linked Sodium Alginate Microspheres with Different Metal Ions Using the Microfluidic Electrospray Technology

Preparation of Cross-Linked Sodium Alginate Microspheres with Different Metal Ions Using the Microfluidic Electrospray Technology

Published on: June 7, 2024

Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform

Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform

Published on: October 20, 2020

Related Experiment Videos

Last Updated: Jun 3, 2026

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Preparation of Cross-Linked Sodium Alginate Microspheres with Different Metal Ions Using the Microfluidic Electrospray Technology

Preparation of Cross-Linked Sodium Alginate Microspheres with Different Metal Ions Using the Microfluidic Electrospray Technology

Published on: June 7, 2024

Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform

Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform

Published on: October 20, 2020

Area of Science:

Biomaterials Science
Drug Delivery Systems
Immunology

Background:

Interferon alpha-2b (IFNα-2b) is a crucial immune regulator with clinical applications.
Frequent injections and toxicity limit IFNα-2b patient compliance.
Developing controlled-release systems is vital for effective IFNα-2b therapy.

Purpose of the Study:

To develop and optimize microspheres for sustained and stable delivery of IFNα-2b.
To maintain the activity of IFNα-2b during the formulation process.
To achieve a zero-order release profile for prolonged therapeutic effect.

Main Methods:

IFNα-2b was solidified into microparticles via co-lyophilization with gelatin and ZnSO(4).
Microspheres were prepared using a water-in-oil-in-water (S/O/W) emulsion method with a PEGT/PBT-PLGA matrix.
Formulation and preparation procedures were optimized for encapsulation efficiency and in vitro release.

Main Results:

Optimized microspheres (28.94 μm) achieved 86.01% encapsulation efficiency.
In vitro studies showed a 16.69% burst release and 83.06% cumulative release by day 23, following a zero-order profile.
In vivo studies in rats demonstrated sustained and steady IFNα-2b release for approximately 13 days.

Conclusions:

The developed microsphere formulation effectively preserves IFNα-2b activity.
The S/O/W method provides a successful strategy for sustained and complete IFNα-2b release.
This approach offers a promising alternative to frequent injections, potentially improving patient compliance.